CCConstantinos Chrysostomou

Constantinos Chrysostomou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Constantinos Chrysostomou has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Phase II/III, Multicenter, Safety, Efficacy, and Pharmacokinetic Study of Dexmedetomidine in Preterm and Term Neonates

    by Constantinos Chrysostomou, Scott R. Schulman, Mario Herrera Castellanos, Benton E. Cofer, Sanjay Mitra, Marcelo Garcia da Rocha, Wayne A. Wisemandle, Lisa Gramlich


  • Short- and intermediate-term survival after extracorporeal membrane oxygenation in children with cardiac disease

    by Constantinos Chrysostomou, Victor O. Morell, Bradley A. Kuch, Elizabeth O’mAlley, Ricardo Munoz, Peter D. Wearden


  • Open Access

    Neurodevelopmental Outcomes after Pediatric Cardiac ECMO Support

    by Constantinos Chrysostomou, Timothy Maul, Patrick M. Callahan, Khoa Nguyen, Steven Lichtenstein, Emma G. Coate, Victor O. Morell, Peter Wearden

    Purpose: To characterize the neurodevelopmental outcomes and identify factors associated with poor outcomes in pediatric patients undergoing cardiac extracorporeal membrane oxygenation (ECMO). Methods: Five year retrospective review, including demographics, cardiac lesion, and surgical complexity, reason for ECMO, ECMO complications, and neurodevelopmental status at discharge and latest follow-up. Neurodevelopmental status was determined through the Pediatric Overall Performance Category and Pediatric Cerebral Performance Category Scales. Results: Overall ECMO survival was 73% at hospital discharge and 66% a t the latest follow-up. Most patients underwent cardiopulmonary resuscitation (CPR) (43%), and the majority (53%) had a significant disease complexity (Aristotle = 4). Complications occurred in 42% of the ECMO runs, of which 12% were intracranial injuries. At hospital discharge, 75% of patients had normal to mild disability, improving to 81% at 2 years follow-up. At hospital discharge, moderate to severe disability was associated with CPR, plasma exchange or intracranial insults. After discharge, 23% showed improvement in neurologic status and 4% showed deterioration. Cerebral infarction was the only parameter associated with deterioration at the later follow-up stage. Conclusion: Extracorporeal membrane oxygenation was successfully used in children with cardiac disease with 73 and 66% short and long-term survival respectively. Majority of the survivors had normal to mild neurodevelopmental disability and a significant portion showed neurologic improvement by the latest follow-up. Nevertheless, despite the grossly favorable outcomes standardized comprehensive neuropsychological testing is of paramount importance in all these patients.


  • Dexmedetomidine: Therapeutic Use for the Termination of Reentrant Supraventricular Tachycardia

    by Constantinos Chrysostomou, Victor O. Morell, Peter Wearden, Joan Sanchez-De-Toledo, Edmund H. Jooste, Lee Beerman

    Objectives. The current drug of choice for reentrant supraventricular tachycardia (SVT) is adenosine followed by verapamil or diltiazem. Although limitations and significant adverse events have been encountered over the years, an alternative effective and safe agent has not been available. Dexmedetomidine has recently been shown to have potential antiarrhythmic effects, and here we describe our experience in the acute termination of reentrant SVT. Design. Retrospective case series. Setting: Quaternary University Children's Hospital, Cardiac Intensive Care Unit. Patients: Patients who received dexmedetomidine for SVT in the past 5 years. Interventions: None. Outcome Measures: SVT episodes terminated with dexmedetomidine were compared with episodes terminated with adenosine. Results. Fifteen patients, median age of 10 days (6–16), were given 27 doses of dexmedetomidine, mean dose 0.7 ± 0.3 mcg/kg, for a total of 27 episodes of SVT. Successful termination occurred in 26 episodes (96%) at a median time of 30 seconds (20–35). Duration of sinus pause was 0.6 ± 0.2 seconds, there was one episode of hypotension and no bradycardia and sedation lasted for 34 ± 8 minutes. Five patients received 27 doses of adenosine, with an overall successful cardioversion in 17 patients (63%) (P= .0017). Transient bradycardia and hypotension was seen in three patients (11%), agitation in 16 patients (59%), and broncospasm in one patient. Median sinus pause was 2.5 seconds (2–9) (P < .001). Conclusions. Dexmedetomidine appears to have novel antiarrhythmic properties for the acute termination of reentrant SVT. Although adenosine is very effective, dexmedetomidine may prove to possess a more favorable therapeutic profile with increased effectiveness and fewer side effects.


  • Critical Congenital Heart Disease-Utility of Routine Screening for Chromosomal and Other Extracardiac Malformations

    by Kimberly Baker, Joan Sanchez-De-Toledo, Ricardo Munoz, Richard Orr, Shareen Kiray, Dana Shiderly, Michele Clemens, Peter Wearden, Victor O. Morell, Constantinos Chrysostomou

    Objective. Infants with critical congenital heart disease (CHD) can have genetic and other extracardiac malformations, which add to the short‐ and long‐term risk of morbidity and perhaps mortality. We sought to examine our center's practice of screening for extracardiac anomalies and to determine the yield of these tests among specific cardiac diagnostic categories. Design. Retrospective review of infants admitted to the cardiac intensive care unit with a new diagnosis of CHD. Subjects were categorized into six groups: septal defects (SD), conotruncal defects (CTD), single‐ventricle physiology (SV), left‐sided obstructive lesions (LSO), right‐sided obstructive lesions (RSO), and “other” (anomalous pulmonary venous return, Ebstein's anomaly). Screening modalities included genetic testing (karyotype and fluorescent in situ hybridization for 22q11.2 deletion), renal ultrasound (RUS), and head ultrasound (HUS). Results. One hundred forty‐one patients were identified. The incidence of cardiac anomalies was: CTD (36%), SD (18%), SV (18%), LSO (14%), RSO (3%), and “other” (8%). Overall 14% had an abnormal karyotype, 5% had a deletion for 22q11.2, 28% had an abnormal RUS and 22% had abnormal HUS. Patients in SD and SV had the highest incidence of abnormal karyotype (36% and 17%); 22q11.2 deletion was present only in CTD and LSO groups (9% and 7%, respectively); abnormal RUS and HUS were seen relatively uniformly in all categories. Premature infants had significantly higher incidence of renal 43% vs. 24%, and intracranial abnormalities 46% vs. 16%. Conclusion. Infants with critical CHD and particularly premature infants have high incidence of genetic and other extracardiac anomalies. Universal screening for these abnormalities with ultrasonographic and genetic testing maybe warranted because early detection could impact short and long‐term outcomes.


  • Perioperative Use of Dexmedetomidine Is Associated With Decreased Incidence of Ventricular and Supraventricular Tachyarrhythmias After Congenital Cardiac Operations

    by Constantinos Chrysostomou, Joan Sanchez-De-Toledo, Peter Wearden, Edmund H. Jooste, Steven E. Lichtenstein, Patrick M. Callahan, Tunga Suresh, Elizabeth O'Malley, Dana Shiderly, Jamie Haney, et al.


  • Kounis Syndrome or Allergic Coronary Vasospasm in a Two-year-old

    by Brodie Parent, Peter Wearden, Nicholas G. Kounis, Constantinos Chrysostomou

    Kounis syndrome is coronary vasospasm because of mast cell degranulation in the context of an allergic reaction. The syndrome has known associations with several drugs used during anesthesia, including rocuronium and isoflurane. In this case report, we discuss a 2-year-old patient who developed signs and symptoms of an acute coronary syndrome soon after anesthesia for atrial septal defect repair. A diagnostic angiography after the episode revealed diffusely small coronary arteries. Subsequent angiography after clinical improvement showed essentially normal coronary anatomy. We report the clinical course of this patient and postulate that Kounis syndrome was the explanation for his transient coronary vasospasm. To date, this is the youngest known patient with reported Kounis syndrome.


  • Electrocardiographic effects of dexmedetomidine in patients with congenital heart disease

    by Constantinos Chrysostomou, Rukmini Komarlu, Steven Lichtenstein, Dana Shiderly, Gaurav Arora, Richard Orr, Peter D. Wearden, Victor O. Morell, Ricardo Munoz, Edmund H. Jooste

    Objective Assessment of electrocardiographic (ECG) effects of dexmedetomidine. Design Prospective observational study including children 0–17 years of age with congenital heart disease (CHD) and children following cardiothoracic surgery. Patients who did not receive dexmedetomidine were used as a control group. All patients had two ECGs: one baseline, pre-dexmedetomidine (T1) and one during dexmedetomidine infusion (T2). Measurements and results Fifty-one patients, median age of 0.5 years (IQR = 3.4), and 25 patients, age 0.25 (IQR = 2.9), were included in the dexmedetomidine and control groups, respectively. Forty received a dexmedetomidine-loading dose of 1 µg/kg (IQR = 0.5). At T2, the dexmedetomidine infusion was 1 µg/kg/h (IQR = 0.5). In the dexmedetomidine group, heart rate (HR) decreased from 140 ± 22 to 115 ± 23 (P < 0.001); PR, PRc and PR index changed from 115 ± 28 to 122 ± 29 ms (P = 0.01), 174 ± 38 to 167 ± 35 ms (P = 0.07) and 15,882 ± 3,565 to 13,792 ± 3,311 (P < 0.001), respectively. QRS decreased from 84 ± 21 to 80 ± 21 ms (P = 0.02), and QTc had no change (433 ± 47 to 435 ± 36 ms). When compared to the control group, none of the ECG intervals had any difference other than a trend towards lower HR (P = 0.08). Neonates and infants had a bigger drop in the HR compared to older children (P < 0.001), while other parameters were similar. At T2 none of the dexmedetomidine group patients had atrioventricular block or other arrhythmia. Four patients in the control group had accelerated junctional rhythm. Conclusions Use of dexmedetomidine in patients with CHD and patients following cardiothoracic surgery is not associated with any significant ECG interval abnormalities other than a trend towards lower HR.


  • Dexmedetomidine use in a pediatric cardiac intensive care unit: Can we use it in infants after cardiac surgery?

    by Constantinos Chrysostomou, Joan Sanchez De Toledo, Tracy Avolio, Maria V. Motoa, Donald Berry, Victor O. Morell, Richard Orr, Ricardo Munoz

    To assess clinical response of dexmedetomidine alone or in combination with conventional sedatives/analgesics after cardiac surgery. Retrospective study. Pediatric cardiac intensive care unit. Infants and neonates after cardiac surgery. We identified 80 patients including 14 neonates, at mean age and weight of 4.1 +/- 3.1 months and 5.5 +/- 2 kg, respectively, who received dexmedetomidine for 25 +/- 13 hours at an average dose of 0.66 +/- 0.26 microgxkgxhr. Overall normal sleep to moderate sedation was documented 94% of the time and no pain to mild pain for 90%. Systolic blood pressure (SBP) decreased from 89 +/- 15 mm Hg to 85 +/- 11 mm Hg (p = .05), heart rate (HR) from 149 +/- 22 bpm to 129 +/- 16 bpm (p < .001), and respiratory rate (RR) remained unchanged. When baseline arterial blood gases were compared with the most abnormal values, pH decreased from 7.4 +/- 0.07 to 7.37 +/- 0.05 (p = .006), Po2 from 91 +/- 67 mm Hg to 66 +/- 29 mm Hg (p = .005), and CO2 increased from 45 +/- 8 mm Hg to 50 +/- 12 mm Hg (p = .001). At the beginning of the study, 37 patients (46%) were mechanically ventilated; and at 48 hours, 13 patients (16%) were still intubated and five patients failed extubation. Three groups of patients were identified: A, dexmedetomidine only (n = 20); B, dexmedetomidine with sedatives/analgesics (n = 38); and C, dexmedetomidine with both sedatives/analgesics and fentanyl infusion (n = 22). The doses of dexmedetomidine and rescue sedatives/analgesics were not significantly different among the three groups but duration of dexmedetomidine was longer in group C vs. A (p = .03) and C vs. B (p = .002). Pain, sedation, SBP, RR, and arterial blood gases were similar. HR was higher in group C vs. B (p = .01). Comparison between neonates and infants showed that infants required higher dexmedetomidine doses, 0.69 +/- 25 microgxkgxhr, and vs. 0.47 +/- 21 microgxkgxhr (p = .003) and had lower HR (p = .01), and RR (p = .009), and higher SBP (p < .001). Dexmedetomidine use in infants and neonates after cardiac surgery was well tolerated in both intubated and nonintubated patients. It provides an adequate level of sedation/analgesia either alone or in combination with low-dose conventional agents.


  • Pulmonary Atresia with Intact Interventricular Septum

    by Constantinos Chrysostomou, Jacqueline Kreutzer, Victor O. Morell